Price
$9.47-48.84%Social Signal Score
Analyst Ratings
10 analysts52-week range
- Last close
- $9.47
- Off 52w high
- -53.5%
- 200-day average
- $13.07
- vs 200-day
- -27.6%
Revenue
$141.10M+4140.42%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Adam S. Grossman
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 644
- Beta
- 0.77
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 8.51
Financials
Revenue
$141.10M+4140.4%Net Income
$49.88MEBITDA
$70.83MFree Cash Flow
$15.37MEPS (diluted)
$0.22Shares Outstanding (diluted)
225.82M+1652.3%Operating Expenses
$31.05MCash & Debt
$124.56MReturn of Capital
$25.05MRevenue by Segment (annual)
$427.10MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $510.17M | $146.93M | $0.62 |
| 2024 | $426.45M | $197.67M | $0.85 |
| 2023 | $258.21M | $-28.24M | $-0.13 |
| 2022 | $154.08M | $-65.90M | $-0.43 |
| 2021 | $80.94M | $-71.65M | $-0.61 |
| 2020 | $42.22M | $-75.75M | $-1.02 |
| 2019 | $29.35M | $-48.28M | $-1.05 |
| 2018 | $16.99M | $-65.74M | $-1.45 |
| 2017 | $22.76M | $-43.76M | $-1.91 |
| 2016 | $10.66M | $-19.52M | $-1.61 |
| 2015 | $7.18M | $-17.97M | $-1.73 |
| 2014 | $5.92M | $-16.81M | $-1.81 |
| 2013 | $3.07M | $-15.53M | $-2.38 |
| 2012 | $1.12M | $-7.30M | $-1.39 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.91
- Implied price
- $26.27
- Return from $13.17
- 14.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $13.06 — -0.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 25 | 29 | 33 | 37 |
|---|---|---|---|---|---|
| -2.0% | -2.3% | 1.1% | 4.2% | 6.9% | 9.4% |
| 3.0% | 2.7% | 6.3% | 9.5% | 12.4% | 15.0% |
| 8.0% | 7.6% | 11.5% | 14.8% | 17.8% | 20.5% |
| 13.0% | 12.6% | 16.6% | 20.1% | 23.3% | 26.1% |
| 18.0% | 17.6% | 21.8% | 25.4% | 28.7% | 31.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (31)
- Newszacks.com·9d ago·Positive
Here's Why Adma Biologics (ADMA) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·16d ago·Positive
Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average After reaching an important support level, Adma Biologics (ADMA) could be a good stock pick from a technical perspective. ADMA surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
View source ↗ - Newszacks.com·16d ago·Positive
Adma Biologics (ADMA) Recently Broke Out Above the 200-Day Moving Average From a technical perspective, Adma Biologics (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript ADMA Biologics, Inc. (ADMA) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·18d ago·Positive
Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates Adma Biologics (ADMA) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.
View source ↗ - Newsmarketbeat.com·18d ago·Positive
ADMA Biologics Q3 Earnings Call Highlights ADMA Biologics NASDAQ: ADMA raised its minimum full-year earnings expectations after third-quarter profit rose on stronger sales of ASCENIV and improved manufacturing yields, even as competitive pressure weighed on its BIVIGAM product.
View source ↗ - Newszacks.com·23d ago·Negative
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note In the closing of the recent trading day, Adma Biologics (ADMA) stood at $11.41, denoting a -2.89% move from the preceding trading day.
View source ↗ - Newszacks.com·24d ago·Neutral
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
View source ↗ - Newszacks.com·24d ago·Neutral
Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know Adma Biologics (ADMA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026 RAMSEY, N.J. and BOCA RATON, Fla.
View source ↗ - Newszacks.com·33d ago·Neutral
Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing Adma Biologics (ADMA) closed the most recent trading day at $11.24, moving +1.49% from the previous trading session.
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
ADMA Biologics Announces Peer-Reviewed Publication Highlighting New Data From Its Optimized, Proprietary IVIG Manufacturing Process Optimized Process Demonstrated Effective Removal of Procoagulant Impurities While Maintaining Immunoglobulin Quality and Increasing IgG Yield
View source ↗ - Newszacks.com·41d ago·Neutral
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
View source ↗ - Newszacks.com·45d ago·Neutral
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors In the latest trading session, Adma Biologics (ADMA) closed at $10.33, marking a +1.87% move from the previous day.
View source ↗ - Newszacks.com·45d ago·Neutral
ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to Adma Biologics (ADMA). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newszacks.com·54d ago·Neutral
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market In the most recent trading session, Adma Biologics (ADMA) closed at $10, indicating a -1.24% shift from the previous trading day.
View source ↗ - Newszacks.com·59d ago·Neutral
Why Adma Biologics (ADMA) Dipped More Than Broader Market Today Adma Biologics (ADMA) closed at $9.52 in the latest trading session, marking a -1.86% move from the prior day.
View source ↗ - Newszacks.com·59d ago·Neutral
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
View source ↗ - Newszacks.com·65d ago·Positive
Adma Biologics (ADMA) Outpaces Stock Market Gains: What You Should Know Adma Biologics (ADMA) closed the most recent trading day at $9.13, moving +2.01% from the previous trading session.
View source ↗ - Newsnewsfilecorp.com·69d ago·Neutral
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA) Philadelphia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite …
View source ↗ - Newszacks.com·72d ago·Negative
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know Adma Biologics (ADMA) reached $9.23 at the closing of the latest trading day, reflecting a -1.7% change compared to its last close.
View source ↗ - Newszacks.com·73d ago·Neutral
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know Adma Biologics (ADMA) closed at $9.36 in the latest trading session, marking a -1.01% move from the prior day.
View source ↗ - Newszacks.com·75d ago·Neutral
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
View source ↗ - Newsprnewswire.com·75d ago·Neutral
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) PHILADELPHIA, Sept. 8, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company").
View source ↗ - Newszacks.com·79d ago·Neutral
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound? Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsprnewswire.com·83d ago·Neutral
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) PHILADELPHIA, Aug. 31, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand…
View source ↗ - Newsnewsfilecorp.com·90d ago·Neutral
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA) Philadelphia, Pennsylvania--(Newsfile Corp. - August 24, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite dec…
View source ↗ - Newsprnewswire.com·97d ago·Neutral
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) PHILADELPHIA, Aug. 17, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite declining demand…
View source ↗ - Newszacks.com·101d ago·Neutral
Can Asceniv Help ADMA Stock Combat IG Market Challenges? Asceniv drives ADMA's growth with rising adoption and real-world evidence, while competitive pressure weighs on Bivigam sales.
View source ↗ - Newsseekingalpha.com·102d ago·Neutral
ADMA Biologics: The Earnings Reset Still Leaves More Upside ADMA Biologics faces a lower earnings base after some challenging times, but ASCENIV remains its key growth driver. Despite reduced long-term targets, Q2 saw ASCENIV revenue up 24%, gross margin at 69%, and improved receivable collection, supporting valuation confidence. My Buy thesis rests on continued ASCENIV growth from the reset base, not a reversal of prior shocks or restored guidance.
View source ↗ - Newsnewsfilecorp.com·102d ago·Neutral
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA) Philadelphia, Pennsylvania--(Newsfile Corp. - August 12, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA" or the "Company"). The investigation is focused on whether the Company engaged in channel-stuffing to drive revenue growth despite dec
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $0.22 per share
Typical surprise +3.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$0.23 vs $0.20beat
- Wed, Aug 5$0.16 vs $0.16miss
- Wed, May 6$0.19 vs $0.19miss
- Wed, Feb 25$0.20 vs $0.18beat
- Wed, Nov 5$0.16 vs $0.16beat
- Wed, Aug 6$0.15 vs $0.14beat
Estimates and results for ADMA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ADMA officers and directors.
- Bought
- $468k
- Sold
- $5.2m
5 trades
22 trades
- Guiheen Lawrence P.sold
- Grossman Adam Ssold
- Grossman Adam Ssold
- Grossman Adam Ssold
- Grossman Adam Ssold
- Grossman Jerrold Bbought
- Grossman Jerrold Bbought
- Grossman Jerrold Bbought
73 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ADMA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
